ImmuPharma PLC

Thermo Fisher Scientific has been selected by ImmuPharma as the key drug product and contract development manufacturer for its Kapiglucagon diabetes treatment program. The partnership covers development and manufacturing support for Kapiglucagon, an experimental therapy aimed at addressing diabetes. This agreement adds a new project to Thermo Fisher Scientific's pharmaceutical services portfolio, focused on complex drug development work. The Kapiglucagon mandate is part of a broader industry shift in which drug developers frequently work with external partners for specialized development and production capabilities. Thermo Fisher Scientific reported second quarter 2026 sales of US$11.99 billion and net income of US$1.74 billion, and continued to return capital via share repurchases.

Seeing Machines has won a new driver monitoring contract with a European carmaker worth around $5 million in lifetime revenue, as new EU safety rules make the technology mandatory on new vehicles. Production starts in 2028, with the system built into a rear-view mirror for easy deployment across multiple platforms. Frontier IP portfolio company Cambridge Raman Imaging has secured a €400,000 European grant to scale up its AI-powered pharmaceutical quality control technology and appointed a China-based distributor with over 100 customers globally. ImmuPharma has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon, completing the main manufacturing partnerships alongside Swiss group Bachem, which is handling the active ingredient. MP Evans grew crude palm oil production 11% to 192,300 tonnes in the first half, supported by higher harvests across its Indonesian estates, with pricing holding firm at around $873 per tonne. Ariana Resources says its Tavşan gold mine in Türkiye has completed its ramp-up and is now processing ore at the required rate of at least 4,000 tonnes a day, with gold recovery tracking at around 70%. 88 Energy has moved its Augusta-1 Alaska well closer to a first-quarter 2027 spud after securing a rig and camp, and prospective resources at South Prudhoe have been upgraded by 35%.

Tower Resources has raised £400,000 to bolster working capital while it waits on government approvals in Namibia and Cameroon, with both farm-out deals potentially completing as early as July. Buccaneer Energy reported an 18% rise in proved reserves in an independent review tied to its bank credit facility, with the borrowing base confirmed at $4.45 million and more growth expected as production ramps up. Light Science Technologies secured up to £1.66 million in orders for its passive fire protection division since April's RLUK Injection acquisition, becoming a vertically integrated business spanning installation and material supply. Eco Buildings Group has started building a second-generation AI-enabled manufacturing line in Albania, the first major use of its recent £2.35 million fundraise, with the new line expected to be operational by the fourth quarter. Fieldwork Robotics, backed by Frontier IP Group, picked up a £300,000 investment from SEED Innovations to roll out its soft fruit harvesting robots, with multi-robot fleets potentially on farms from 2027 if trials succeed. ImmuPharma flagged new research suggesting its lead drug candidate could help treat glioblastoma, an aggressive brain cancer, while its main focus remains autoimmune disease.